Citations

Clear

3942 citation(s) found for "To, Van".

Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?
Lemoinne, Sara , Soret, Pierre‐Antoine , Gulamhusein, Aliya , Lytvyak, Ellina , Olivas, Ignasi , Eaton, John E. , Sebode, Marcial , Lohse, Ansgar W. , Nevens, Frederik , Cazzagon, Nora , Zago, Alessandra , Russo, Francesco Paolo , Floreani, Annarosa , Abbas, Nadir , Thorburn, Douglas , Delamarre, Adèle , Sobenko, Natalia , Villamil, Alejandra , Patwardhan, Vilas , Rigamonti, Cristina , Meer, Adriaan van der , Veer, Rozanne de, Zigmond, Ehud , Yehezkel, Eyal , Bruns, Tony , Große, Karsten , Wetten, Aaron , Jones, David , Dumortier, Jérôme , Pageaux, Georges‐Philippe , Lédinghen, Victor de , Chazouillères, Olivier , Groups, the Global & ERN Rare-Liver PBC Study, Osman, Karim T. , Bruns, Tony , Patwardhan, Vilas R , Lytvyak, Ellina , Corpechot, Christophe , Hansen, Bettina E. , Hirschfield, Gideon M. , Montaño‐Loza, Aldo J. , Parés, Albert , Schramm, Christoph , Dalekos, George Ν. , Gatselis, Nikolaos , Abbas, Nadir , Trivedi, Palak Jitendrakumar , Saffioti, Francesca , Barkai, László , Roccarina, Davide , Calvaruso, Vincenza , Fichera, Anna, Villamil, Alejandra , Medina‐Morales, Esli , Bonder, Alan , Carbone, Marco , Invernizzi, Pietro , Cristoferi, Laura , Kremer, Andreas E. , Deibel, Ansgar , Dyson, Jessica Katharine , Carrat, Fabrice , Groups, the Global & ERN Rare-Liver PBC Study, Russo, Francesco Paolo

Mayo Clinic

Hepatology | September 21, 2023 | Volume: 79 | Issue: 1 | Pages: 39-48

10.1097/hep.0000000000000529 | PMID 37399238 Get It

Background and Aims: Normal alkaline phosphatase (ALP) levels in ursodeoxycholic acid (UDCA)-treated patients with primary biliary cholangitis (PBC) are associated with better long-term outcome. However, second-line therapies are currently recommended only when ALP levels remain above 1.5 times the upper limit of normal (×ULN) after 12-month UDCA. We assessed whether, in patients considered good responders to UDCA, normal ALP levels were associated with significant survival gains. Approach and Results: We performed a retrospective cohort study of 1047 patients with PBC who attained an adequate response to UDCA according to Paris-2 criteria. Time to liver-related complications, liver transplantation, or death was assessed using adjusted restricted mean survival time (RMST) analysis. The overall incidence rate of events was 17.0 (95% CI: 13.7–21.1) per 1000 out of 4763.2 patient-years. On the whole population, normal serum ALP values (but not normal gamma-glutamyl transpeptidase (GGT), alanine aminotransferase (ALT), or aspartate aminotransferase (AST); or total bilirubin < 0.6 ×ULN) were associated with a significant absolute complication-free survival gain at 10 years (mean 7.6 months, 95% CI: 2.7 - 12.6 mo.; p = 0.003). In subgroup analysis, this association was significant in patients with a liver stiffness measurement ≥ 10 kPa and/or age ≤ 62 years, with a 10-year absolute complication-free survival gain of 52.8 months (95% CI: 45.7–59.9, p < 0.001) when these 2 conditions were met. Conclusions: PBC patients with an adequate response to UDCA and persistent ALP elevation between 1.1 and 1.5 ×ULN, particularly those with advanced fibrosis and/or who are sufficiently young, remain at risk of poor outcome. Further therapeutic efforts should be considered for these patients.
Withdrawal of bevacizumab is associated with rebound growth of vestibular schwannomas in neurofibromatosis type 2-related schwannomatosis patients
Webb, Mason , Neth, Bryan J. , Webb, Lauren M. , Link, Michael J., Neff, Brian A., Carlson, Matthew L. , Driscoll, Colin L. W., Dornhoffer, Jim R., Ruff, Michael W. , Anderson, Kelsey A, Kizilbash, Sani H. , Campian, Jian , Uhm, Joon H. , Lane, Jack I, Blezek, Daniel J. , Mehta, P. , Sener, Uğur , Driscoll, Colin L., Dornhoffer, Jim, Benson, John C. , Mehta, Parv M, Sener, Ugur T, Neth, Byran J. , Kizilbash, Sani H , Sener, Ugur , Webb, Mason James , Mehta, Parv , Gompel, Jamie J. Van , Link, Michael J. , Lane, Jack I., Bathla, Girish

Mayo Clinic

Neuro-Oncology Advances | September 20, 2023 | Volume: 5 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdad123 | PMID 37841698 Get It

Abstract Background Neurofibromatosis type 2 (NF2)-related schwannomatosis is an autosomal dominant tumor-predisposition syndrome characterized by bilateral vestibular schwannomas (VS). In patients with VS associated with NF2, vascular endothelial growth factor A inhibitor, bevacizumab, is a systemic treatment option. The aim of this study is to retrospectively evaluate NF2 patient responses to bevacizumab on VS growth and symptom progression. Methods This is a retrospective analysis of patients seen at the Mayo Clinic Rochester Multidisciplinary NF2 Clinic. Results Out of 76 patients with NF2 evaluated between 2020 and 2022, we identified 19 that received treatment with bevacizumab. Thirteen of these patients discontinued bevacizumab after median treatment duration of 12.2 months. The remaining 6 patients are currently receiving bevacizumab treatment for a median duration of 9.4 months as of March, 2023. Fifteen patients had evaluable brain MRI data, which demonstrated partial responses in 5 patients, stable disease in 8, and progression in 2. Within 6 months of bevacizumab discontinuation, 5 patients had rebound growth of their VS greater than 20% from their previous tumor volume, while 3 did not. Three patients with rebound growth went on to have surgery or irradiation for VS management. Conclusions Our single-institution experience confirms prior studies that bevacizumab can control progression of VS and symptoms associated with VS growth. However, we note that there is the potential for rapid VS growth following bevacizumab discontinuation, for which we propose heightened surveillance imaging and symptom monitoring for at least 6 months upon stopping anti-VEGF therapy.
Anatomic Variants in the Anterior Inferior Cerebellar Artery Encountered During Resection of Vestibular Schwannomas
Carlstrom, Lucas P. , Dornhoffer, James R. , Randall, Nicholas R. , Celda, María Peris, Driscoll, Colin L. W., Carlson, Matthew L. , Link, Michael J. , Peris Celda, Maria, Driscoll, Colin L., Gompel, Jamie J. Van

Mayo Clinic

Operative Neurosurgery | September 20, 2023 | Volume: 25 | Issue: 6 | Pages: 512-520

10.1227/ons.0000000000000881 | PMID 37729626 Get It

BACKGROUND AND OBJECTIVES: Vestibular schwannomas (VS) are often phenotypically benign lesions that may be technically challenging to resect because of involvement of neurovascular structures. The anterior inferior cerebellar artery (AICA) is commonly identified near VS, with variable position in relation to the tumor; however, little published literature describes anatomic and pathologic variants of AICA observed during VS resection. METHODS: A prospectively maintained cohort of surgically managed VS with available operative reports and clinical/radiographic follow-up was queried and reviewed for noted aberrations. RESULTS: We identified 66 cases with noted AICA abnormalities among 880 reviewer cases, including 20 loops extending into the internal auditory canal (2.3%), 18 arteries embedded in dura (2.0%), 15 AICA branches directly within VS (1.7%), 8 main trunk arteries coursing between cranial nerves 7 and 8 (0.9%), 3 arteries embedded in temporal bone (0.2%), 1 aneurysm (0.1%), and 1 artery bifurcating cranial nerve 6 (0.1%). The median age of AICA-variant patients was 55 years (range 19-74), and 29 were female (45%). Compared with the other AICA variants, tumors embedded with AICA tended to be larger lesions on maximal axial diameter (2.9 vs 1.6 cm; P = .006), they more commonly underwent less than total resection (73% vs 28%; P = .0001), and they had higher rates postoperative House-Brackmann scores >2 (47% vs 20%; P = .005). Two patients had radiographic and symptomatic postoperative cerebral ischemia or hemorrhage—1 from a bone-encased AICA and 1 from a dural embedded variant. CONCLUSION: Anatomic variants of AICA occur in approximately 7% of VS operations. Most aberrations do not affect surgical or clinical outcomes, and the rate of major vascular injury was low. However, certain types variably add operative time and in the case of AICA encasement in the tumor, likely indicate a more aggressive tumor phenotype with lower rates of gross total resection and high incidences of facial nerve weakness.
Tumor-Infiltrating Normal B Cells Revealed by Immunoglobulin Repertoire Clonotype Analysis Are Highly Prognostic and Crucial for Antitumor Immune Responses in DLBCL
Xu‐Monette, Zijun Y. , Li, Yong , Snyder, Thomas M. , Yu, Tiantian , Lu, Tingxun , Tzankov, Alexandar , Visco, Carlo , Bhagat, Govind , Qian, Wenbin , Dybkær, Karen , Chiu, April , Tam, Wayne , Zu, Youli , Hagemeister, Fredrick B., Wang, Yingjun , Ferreri, Andrés J.M. , Møller, Michael , Parsons, Benjamin M. , Fan, Xiangshan , Au, Qingyan , Zhang, Mingzhi , Shaughnessy, John D. , Xu, Bing , Young, Ken H. , Snyder, Thomas , Lu, Tingxun , Hsi, Eric D , Hagemeister, Fredrick B , Wang, Yingjun , Go, Heounjeong , Ponzoni, Maurilio , Ferreri, Andrés J M , Møller, Michael Boe , Parsons, Benjamin M , Fan, Xiangshan , van Krieken, J Han , Piris, Miguel , Winter, Jane N , Au, Qingyan , Kirsch, Ilan , Zhang, Mingzhi , Shaughnessy, John , Xu, Bing , Young, Ken H , Tzankov, Alexandar , Dybkaer, Karen , Li, Yong , Bhagat, Govind , Zu, Youli , Xu-Monette, Zijun Y , Hsi, Eric D. , Go, Heounjeong , Ponzoni, Maurilio , Krieken, J. Han van , Piris, Miguel Á. , Winter, Jane N. , Kirsch, Ilan R.

Mayo Clinic

Clinical Cancer Research | September 20, 2023 | Volume: 29 | Issue: 23 | Pages: 4808-4821

10.1158/1078-0432.ccr-23-1554 | PMID 37728879 Get It

Abstract Purpose: Tumor-infiltrating B lymphocytes (TIL-B) have demonstrated prognostic and predictive significance in solid cancers. In this study, we aimed to distinguish TIL-Bs from malignant B-cells in diffuse large B-cell lymphoma (DLBCL) and determine the clinical and biological significance. Experimental Design: A total of 269 patients with de novo DLBCL from the International DLBCL R-CHOP Consortium Program were studied. Ultra-deep sequencing of the immunoglobulin genes was performed to determine B-cell clonotypes. The frequencies and numbers of TIL-B clonotypes in individual repertoires were correlated with patient survival, gene expression profiling (GEP) data, and frequencies of DLBCL-infiltrating immune cells quantified by fluorescent multiplex IHC at single-cell resolution. Results: TIL-B abundance, evaluated by frequencies of normal B-cell clonotypes in the immunoglobulin repertoires, remarkably showed positive associations with significantly better survival of patients in our sequenced cohorts. DLBCLs with high versus low TIL-B abundance displayed distinct GEP signatures, increased pre-memory B-cell state and naïve CD4 T-cell state fractions, and higher CD4+ T-cell infiltration. TIL-B frequency, as a new biomarker in DLBCL, outperformed the germinal center (GC) B-cell–like/activated B-cell–like classification and TIL-T frequency. The identified TIL-B–high GEP signature, including genes upregulated during T-dependent B-cell activation and those highly expressed in normal GC B cells and T cells, showed significant favorable prognostic effects in several external validation cohorts. Conclusions: TIL-B frequency is a significant prognostic factor in DLBCL and plays a crucial role in antitumor immune responses. This study provides novel insights into the prognostic determinants in DLBCL and TIL-B functions with important therapeutic implications.
Integrated safety analysis of filgotinib for ulcerative colitis: Results from SELECTION and SELECTIONLTE
Schreiber, Stefan , Rogler, Gerhard , Watanabe, Mamoru , Vermeire, Séverine , Maaser, Christian , Faes, Margaux , Hoek, Paul Van , Hsieh, Jeremy, Moerch, Ulrik, Haas, Angela de, Rudolph, Christine , Oortwijn, Alessandra , Loftus, Edward V. , Danese, Silvio , Oortwijn, Alessandra , Loftus, Edward V , Vermeire, Séverine , Danese, Silvio , Zhou, Yan

Mayo Clinic

Alimentary Pharmacology & Therapeutics | September 18, 2023 | Volume: 58 | Issue: 9 | Pages: 874-887

10.1111/apt.17674 | PMID 37718932 Get It

Summary Background Filgotinib 200 mg (FIL200) is an approved treatment for adults with moderately to severely active ulcerative colitis (UC). Aim To report integrated safety data from the phase 2b/3 SELECTION study (NCT02914522) and its ongoing long‐term extension study SELECTIONLTE (NCT02914535). Methods Safety outcomes were analysed in adults with moderately to severely active UC who received FIL200, filgotinib 100 mg (FIL100) or placebo once daily throughout the 11‐week SELECTION induction study, the 47‐week SELECTION maintenance study (if applicable) and SELECTIONLTE (if applicable). Exposure‐adjusted incidence rates (EAIRs) per 100 censored patient‐years of exposure with 95% confidence intervals were reported for treatment‐emergent adverse events (AEs). Certain AE data were presented in subgroups, including age and prior biologic exposure status. Results This interim analysis included 1348 patients representing 3326.2 patient‐years of exposure. Baseline characteristics of patients entering SELECTION were similar across treatment groups. EAIRs for serious infection, thromboembolic events and major adverse cardiovascular events (MACE) were consistently low across treatment groups. Most patients with MACE had cardiovascular risk factors. The EAIR for herpes zoster was numerically higher for FIL200 than for placebo. Infection incidences were numerically higher in biologic‐experienced than biologic‐naive patients. Higher incidences of certain AEs in patients 65 years of age or older were as expected. Four deaths occurred, including three cardiovascular deaths, none of which was considered related to filgotinib. Conclusion FIL200 and FIL100 were well tolerated with no unexpected safety signals in patients with moderately to severely active UC, regardless of previous biologic exposure or age. ClinicalTrials.gov Identifiers (NCT numbers) NCT02914522, NCT02914535.
TRAPPC6B biallelic variants cause a neurodevelopmental disorder with TRAPP II and trafficking disruptions
Almousa, Hashem , Lewis, Sara A. , Bakhtiari, Somayeh , Nordlie, Sandra H., Pagnozzi, Alex M. , Magee, Helen, Efthymiou, Stéphanie , Heim, Jennifer, Anwar, Najwa, Maqbool, Shazia , Rahman, Fatima , Neilson, Derek , Vemuri, Anusha, Jin, Sheng Chih , Yang, Xiao‐Ru, Heidari, Abolfazl, Trimouille, Aurélien , Thauvin‐Robinet, Christel , Liu, James, Bruel, Ange‐Line , Tomoum, Hoda , Shata, Mennatallah Osama , Hashem, Mais O, Karimiani, Ehsan Ghayoor , Lingappa, Lokesh , Baruah, Debangana, Ebrahimzadeh, Farnoosh , Van‐Gils, Julien , Faivre, Laurence , Galehdari, Hamid, Sadeghian, Saeid , Mohammad, Rahema, Smagt, Jasper J. van der , Qari, Alya , Akar, Halil Tuna , Bilgüvar, Kaya , Mignot, Cyril , Keren, Boris , Raveli, Claudia, Afenjar, Alexandra , Kaat, Laura Donker , Slegtenhorst, Marjon van, Alkuraya, Fowzan S. , Houlden, Henry , Padilla‐Lopez, Sergio , Maroofian, Reza , Sacher, Michael , Kruer, Michael C. , Cornejo, Patricia , Jin, Sheng Chih , Zamani, Mina , Sadeghian, Saeid , Alkuraya, Fowzan S , Houlden, Henry , Maroofian, Reza , Sacher, Michael , Faivre, Laurence , Donker Kaat, Laura , Zaki, Maha S. , Gassen, Koen L.I. van , Hashem, Mais O, Toosi, Mehran Beiraghi , Yeşil, Gözde , Galehdari, Hamid , Shariati, Gholamreza , Vincent, John B. , Innes, A. Micheil , Dursun, Ali , Özgül, Rıza Köksal , Bürglen, Lydie

Mayo Clinic

Brain | September 15, 2023 | Volume: 147 | Issue: 1 | Pages: 311-324

10.1093/brain/awad301 | PMID 37713627 Get It

Abstract Highly conserved transport protein particle (TRAPP) complexes regulate subcellular trafficking pathways. Accurate protein trafficking has been increasingly recognized to be critically important for normal development, particularly in the nervous system. Variants in most TRAPP complex subunits have been found to lead to neurodevelopmental disorders with diverse but overlapping phenotypes. We expand on limited prior reports on TRAPPC6B with detailed clinical and neuroradiologic assessments, and studies on mechanisms of disease, and new types of variants. We describe 29 additional patients from 18 independent families with biallelic variants in TRAPPC6B. We identified seven homozygous nonsense (n = 12 patients) and eight canonical splice-site variants (n = 17 patients). In addition, we identified one patient with compound heterozygous splice-site/missense variants with a milder phenotype and one patient with homozygous missense variants. Patients displayed non-progressive microcephaly, global developmental delay/intellectual disability, epilepsy and absent expressive language. Movement disorders including stereotypies, spasticity and dystonia were also observed. Brain imaging revealed reductions in cortex, cerebellum and corpus callosum size with frequent white matter hyperintensity. Volumetric measurements indicated globally diminished volume rather than specific regional losses. We identified a reduced rate of trafficking into the Golgi apparatus and Golgi fragmentation in patient-derived fibroblasts that was rescued by wild-type TRAPPC6B. Molecular studies revealed a weakened interaction between mutant TRAPPC6B (c.454C&gt;T, p.Q152*) and its TRAPP binding partner TRAPPC3. Patient-derived fibroblasts from the TRAPPC6B (c.454C&gt;T, p.Q152*) variant displayed reduced levels of TRAPPC6B as well as other TRAPP II complex-specific members (TRAPPC9 and TRAPPC10). Interestingly, the levels of the TRAPPC6B homologue TRAPPC6A were found to be elevated. Moreover, co-immunoprecipitation experiments showed that TRAPPC6A co-precipitates equally with TRAPP II and TRAPP III, while TRAPPC6B co-precipitates significantly more with TRAPP II, suggesting enrichment of the protein in the TRAPP II complex. This implies that variants in TRAPPC6B may preferentially affect TRAPP II functions compared to TRAPP III functions. Finally, we assessed phenotypes in a Drosophila TRAPPC6B-deficiency model. Neuronal TRAPPC6B knockdown impaired locomotion and led to wing posture defects, supporting a role for TRAPPC6B in neuromotor function. Our findings confirm the association of damaging biallelic TRAPPC6B variants with microcephaly, intellectual disability, language impairments, and epilepsy. A subset of patients also exhibited dystonia and/or spasticity with impaired ambulation. These features overlap with disorders arising from pathogenic variants in other TRAPP subunits, particularly components of the TRAPP II complex. These findings suggest that TRAPPC6B is essential for brain development and function, and TRAPP II complex activity may be particularly relevant for mediating this function.
Abstract PO-039: Discovery and validation of methylated DNA markers of human papillomavirus associated oropharyngeal squamous cell carcinoma
Gochanour, Benjamin R. , Cao, Xiaoming , Then, Sara S., Burger, Kelli N. , Routman, David M. , Bartemes, Kathleen R. , Taylor, William R. , Mahoney, Douglas W. , Graham, Rondell P. , Berger, Calise K. , Doering, Karen A. , Foote, Patrick H. , Kisiel, John B. , Abel, Kathryn M. Van

Mayo Clinic

Clinical Cancer Research | September 15, 2023 | Volume: 29 | Issue: 18_Supplement | Pages: PO-039-PO-039

10.1158/1557-3265.aacrahns23-po-039 Get It

Abstract Background: Reliable non-invasive biomarkers for human papillomavirus (HPV) associated oropharyngeal squamous cell carcinoma (OPX) are lacking. We performed a discovery and validation study of methylated DNA markers (MDMs) for detection of OPX. In addition, we sought to evaluate the MDM profiles in saliva gargle samples from normal controls (nSAL). Methods: Formalin fixed paraffin embedded OPX and gender-balanced normal oropharyngeal tissue (NOP) were pathologically reviewed and punched for DNA extraction and sequenced using reduced representation bisulfite sequencing (RRBS). A tiling algorithm was used to define candidate MDMs. Highest ranked (e.g., area under the receiver operating characteristic curve (AUC), fold-change, p-value) candidate MDMs were validated by qMSP in independent OPX and NOP samples. nSAL DNA was used to assess MDM background signal. Discrimination between OPX tissue, NOP, and nSAL was assessed using AUC with corresponding 95% confidence intervals. HPV was confirmed with p16 staining or DNA in situ hybridization. Results: RRBS discovery assessed 18 OPX, 18 NOP, and 18 normal WBC samples. 234 MDM candidates from approximately 3 × 106 CpGs at &gt;10X coverage were identified. 36 MDMs were selected for validation in independent patient samples which included 32 OPX, 36 NOP, and 35 nSAL specimens. OPX patients were older (median 51; IQR 45-54 years) than NOP patients (median 29; IQR 24-42). 69 and 61% of OPX and NOP patients were female, respectively. The majority of OPX patients were Stage I (n=27, 84%). We observed excellent discrimination between OPX and NOP in the validation set; the median AUC across 36 MDMs was 0.90 (IQR 0.87-0.95). The 10 highest performing markers (PARP15, EPDR1, SHROOM1, EMBP1.rs, IFFO1, MAX.chr19.118, ZNF763, ITGB4, FAM19A2, and MT1IP) exhibited AUCs ranging from 0.95-0.99. Strong discrimination was also observed between OPX and nSAL (Median AUC=0.97; IQR=0.93-0.99). All 10 of the highest-performing markers in tissue exhibited AUCs of at least 0.97 for discriminating OPX versus nSAL. Median fold change between NOP and nSAL across all MDMs was 1.9 (IQR 1.4-3.8), demonstrating low background signal in nSAL. Conclusions: We found strong discrimination in a panel of 36 MDMs between OPX case and control tissue as well as between OPX case tissue and normal saliva. The low background signal observed in normal saliva makes this media a strong candidate for non-invasive detection of OPX. Further studies are in development to assess the utility of measuring these MDMs in both case and control saliva and blood for detecting OPX non-invasively. Citation Format: Benjamin R. Gochanour, David M. Routman, Kathleen R. Bartemes, William R. Taylor, Douglas W. Mahoney, Rondell P. Graham, Xiaoming Cao, Calise K. Berger, Sara S. Then, Karen A. Doering, Kelli N. Burger, Patrick H. Foote, John B. Kisiel, Kathryn M. Van Abel. Discovery and validation of methylated DNA markers of human papillomavirus associated oropharyngeal squamous cell carcinoma [abstract]. In: Proceedings of the AACR-AHNS Head and Neck Cancer Conference: Innovating through Basic, Clinical, and Translational Research; 2023 Jul 7-8; Montreal, QC, Canada. Philadelphia (PA): AACR; Clin Cancer Res 2023;29(18_Suppl):Abstract nr PO-039.
Patient-Reported Outcomes of Omission of Breast Surgery Following Neoadjuvant Systemic Therapy
Lin, Heather , Diego, Emilia J. , Yang, Wei , Valero, Vicente , Mitchell, Melissa P. , White, Richard L. , Rauch, Gaiane M., Kuerer, Henry M. , Group, Exceptional Responders Study, Moseley, Tanya W. , Leung, Jessica WT, Huang, Monica L. , Arribas, Elsa , Parra, Raquel FD van la, Teshome, Mediget , Hwang, Rosa F. , Miggins, Makesha, Piotrowski, Matthew J., Refinetti, Ana P, Ehlers, Richard A., Colen, Jessica Suarez, Loveland‐Jones, Catherine, Lesnikowski, Beth Ann, Samiian, Laila, Chong, Clayton, Arribas, Elsa M , Johnson, Helen Margaret , Shen, Yu , Krishnamurthy, Savitri , Smith, Benjamin D. , Lucci, Anthony , Sun, Susie X. , Shaitelman, Simona Flora , Boughey, Judy C. , Rauch, Gaiane M. , Group, Exceptional Responders Study, Candelaria, Rosalind P. , Adrada, Beatriz E. , Hunt, Kelly K. , Bedrosian, Isabelle

Mayo Clinic

JAMA Network Open | September 14, 2023 | Volume: 6 | Issue: 9 | Pages: e2333933

10.1001/jamanetworkopen.2023.33933 | PMID 37707811 Get It

ImportancePatients should have an active role in decisions about pursuing or forgoing specific therapies in treatment de-escalation trials.ObjectiveTo evaluate longitudinal patient-reported outcomes (PROs) encompassing decisional comfort and health-related quality of life (HRQOL) among patients who elected to enroll in a clinical trial evaluating radiotherapy alone, without breast surgery, for invasive breast cancers with exceptional response to neoadjuvant systemic therapy (NST).Design, Setting, and ParticipantsProspective, single-group, phase 2 clinical trial at 7 US medical centers. Women aged 40 years or older with invasive cT1-2 N0-1 M0 triple-negative or human epidermal growth factor receptor 2 (ERBB2)–positive breast cancer with no pathologic evidence of residual disease following standard NST enrolled from March 6, 2017, to November 9, 2021. Validated PRO measures were administered at baseline and 6, 12, and 36 months post-radiotherapy. Data were analyzed from January to February 2023.InterventionsPRO measures included the Decision Regret Scale (DRS), Functional Assessment of Cancer Therapy—Lymphedema (FACT-B+4), and Breast Cancer Treatment Outcomes Scale (BCTOS).Main Outcomes and MeasuresChanges in PRO measure scores and subscores over time.ResultsAmong 31 patients, the median (IQR) age was 61 (56-66) years, 26 (84%) were White, and 26 (84%) were non-Hispanic. A total of 15 (48%) had triple-negative disease and 16 (52%) had ERBB2-positive disease. Decisional comfort was high at baseline (median [IQR] DRS score 10 [0-25] on a 0-100 scale, with higher scores indicating higher decisional regret) and significantly increased over time (median [IQR] DRS score at 36 months, 0 [0-20]; P &amp;lt; .001). HRQOL was relatively high at baseline (median [IQR] FACT-B composite score 121 [111-134] on a 0-148 scale, with higher scores indicating higher HRQOL) and significantly increased over time (median [IQR] FACT-B score at 36 months, 128 [116-137]; P = .04). Perceived differences between the affected breast and contralateral breast were minimal at baseline (median [IQR] BCTOS score 1.05 [1.00-1.23] on a 1-4 scale, with higher scores indicating greater differences) and increased significantly over time (median [IQR] BCTOS score at 36 months, 1.36 [1.18-1.64]; P &amp;lt; .001). At 36 months postradiotherapy, the cosmetic subscore was 0.45 points higher than baseline (95% CI, 0.16-0.74; P = .001), whereas function, pain, and edema subscores were not significantly different than baseline.Conclusions and RelevanceIn this nonrandomized phase 2 clinical trial, analysis of PROs demonstrated an overall positive experience for trial participants, with longitudinal improvements in decisional comfort and overall HRQOL over time and minimal lasting adverse effects of therapy.Trial RegistrationClinicalTrials.gov Identifier: NCT02945579
Comment on: 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults
Burnett, Allison E., Allen, Arthur L. , Ansell, Jack , Blumenstein, Marilyn, Connors, Jean M. , Dager, William E. , Kaatz, Scott , Nemeth, Ronni, O’Connor, Carlee, Ragheb, Bishoy , Rajasekhar, Anita, Sardo, Laurie A, Beek, Andrea Van, Directors, The Anticoagulation Forum Board of, Allen, Arthur L , O'Connor, Carlee, Burnett, Allison , Barnes, Geoffrey D. , May, Jori E. , Siegal, Deborah , Directors, The Anticoagulation Forum Board of

Mayo Clinic

Journal of the American Geriatrics Society | September 13, 2023 | Volume: 71 | Issue: 12 | Pages: 3951-3953

10.1111/jgs.18579 | PMID 37702478 Get It

See the Reply by Semla and Steinman in this issue.